ArticleAbdominal radiology (New York)2025
Image-guided percutaneous mesenteric biopsy: diagnostic yield and safety profile.
Article in Abdominal radiology (New York), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the diagnostic yield and safety profile of percutaneous image-guided biopsy of mesenteric lesions. MATERIALS, METHODS, AND PROCEDURES: Image-guided percutaneous biopsies of the mesentery at a single institution from 2000 to 2022 were identified and reviewed. Relevant demographic and procedural data were abstracted from the medical record. Surgical pathology was reviewed to evaluate if the biopsy was diagnostic and concordant with the patient's final diagnosis.
resultsOne hundred ninety five patients (mean age, 62.6 ± 14.; M/F, 113/82; mean BMI, 30.4) underwent mesenteric biopsy procedure. Of these, 173 (89%) were performed using ultrasound and 22 (11%) were performed using CT or a hybrid/combined approach. Core needle biopsy was used in 164 (84%) patients, fine-needle aspiration (FNA) was used in 21 (11%), and both were used 10 (5%). Mean/median number of biopsy passes was 2.8 ± 1.3 and 3, respectively (core mean 2.7 ± 1.2; FNA mean 3.4 ± 1.5). Average lesion size was 5.3 ± 4.4 cm in the long axis and 2.9 ± 2.0 cm in the target plane. Diagnostic yield of core biopsies was 97.7% (n = 170/174) and FNA was 80.6% (n = 25/31) for an overall combined yield of 96.4% (n = 188/195). Of diagnostic biopsies, 95.7% (n = 180/188) were concordant with the final diagnosis, 70.8% (n = 138) of which were considered malignant. Overall concordant diagnostic rate was 180/195 (92.3%). Neuroendocrine tumor pathology was the only factor associated with lower diagnostic yield (13/15, 87%). For all biopsies, average shortest skin-to-target-distance on CT was 6.3 ± 2.8 cm, decreased to 4.1 ± 1.3 cm with US compression (approximately 35% reduction, p < 0.001). Additionally, ultrasound created a safe path not available on CT in 29 (15%) biopsies. Moderate IV sedation was used in 91.3% (n = 178) of mesenteric procedures. Complications occurred in 11 (5.6%) biopsies, and all were considered minor.
conclusionThis represents a large cohort of image-guided percutaneous biopsies of mesenteric lesions with the majority representing core biopsy performed under US guidance. This technique offers high diagnostic yield and a favorable safety profile for tissue diagnosis. Furthermore, compression with ultrasound reduced skin-to-target distance by 35% and created a biopsy path that would not be possible on CT in 15% of US cases.
Indexed as
Identifiers
39729098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.